Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS.
Despite major advances in deciphering the neuropathological hallmarks of amyotrophic lateral sclerosis (ALS), validated neurochemical biomarkers for monitoring disease activity, earlier diagnosis, defining prognosis and unlocking key pathophysiological pathways are lacking. Although several candidate biomarkers exist, translation into clinical application is hindered by small sample numbers, especially longitudinal, for independent verification. This review considers the potential routes to the discovery of neurochemical markers in ALS, and provides a consensus statement on standard operating procedures that will facilitate multicenter collaboration, validation and ultimately clinical translation.
Department of Neurology, University of Ulm, Oberer Eselsberg 34, Ulm, Germany. markus.otto@uni-ulm.de
Markus
M
Otto
Robert
R
Bowser
Martin
M
Turner
James
J
Berry
Johannes
J
Brettschneider
James
J
Connor
Júlia
J
Costa
Merit
M
Cudkowicz
Jonathan
J
Glass
Olaf
O
Jahn
Stefan
S
Lehnert
Andrea
A
Malaspina
Lucilla
L
Parnetti
Axel
A
Petzold
Pamela
P
Shaw
Alexander
A
Sherman
Petra
P
Steinacker
Sigurd
S
Süssmuth
Charlotte
C
Teunissen
Hayrettin
H
Tumani
Anna
A
Wuolikainen
Albert
A
Ludolph
D000690:Amyotrophic Lateral Sclerosis / Q000175:diagnosis* / Q000473:pathology / Q000503:physiopathology*; D015415:Biomarkers / Q000378:metabolism*; D001923:Brain Chemistry; D006801:Humans; D040901:Proteomics / Q000379:methods
D015415:Biomarkers